GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » 1-Year Sharpe Ratio

GH (Guardant Health) 1-Year Sharpe Ratio : 0.95 (As of Jul. 08, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Guardant Health 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-07-08), Guardant Health's 1-Year Sharpe Ratio is 0.95.


Competitive Comparison of Guardant Health's 1-Year Sharpe Ratio

For the Diagnostics & Research subindustry, Guardant Health's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health's 1-Year Sharpe Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Guardant Health's 1-Year Sharpe Ratio falls into.


;
;

Guardant Health 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.


Guardant Health  (NAS:GH) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Guardant Health 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Guardant Health's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Executives
Musa Tariq director 3100 HANOVER STREET, PALO ALTO CA 94304
Amirali Talasaz director, officer: Chairman, President and COO 18 ISABELLA AVENUE, ATHERTON CA 94027
Kumud Kalia officer: Chief Information Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Meghan V. Joyce director THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Ines Dahne-steuber officer: Chief Operating Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova officer: Chief Technology Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy director, officer: Chief Executive Officer 2 BARRY LANE, ATHERTON CA 94027
Amelia Merrill officer: SVP, People 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman director 2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Chris Freeman officer: Chief Commercial Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Vijaya Gadde director C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103
Bahija Jallal director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204